Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9

Circulation

Volumn 113, Issue 12, 2006, Pages 1605-1614

  Iwakura, Atsushi ^a   Shastry, Shubha ^a   Luedemann, Corinne ^a   Hamada, Hiromichi ^a   Kawamoto, Atsuhiko ^b   Kishore, Raj ^a   Zhu, Yan ^a   Qin, Gangjian ^a   Silver, Marcy ^a   Thorne, Tina ^a   Eaton, Liz ^a   Masuda, Haruchika ^b   Asahara, Takayuki ^b   Losordo, Douglas W ^a,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Endothelium; Myocardial infarction; Nitric oxide synthase; Stem cells

Indexed keywords

ANGIOPOIETIN RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; GELATINASE B; LECTIN; PLACEBO; VASCULOTROPIN RECEPTOR 2; INDUCIBLE NITRIC OXIDE SYNTHASE; MMP9 PROTEIN, MOUSE; NOS3 PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; ENDOTHELIAL STEM CELL; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; HORMONE SUBSTITUTION; LEFT CORONARY ARTERY; MOUSE; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; STEM CELL MOBILIZATION; ANIMAL; BONE MARROW CELL; CELL MOTION; DRUG EFFECT; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; STEM CELL; TREATMENT OUTCOME;

ANIMALS; BONE MARROW CELLS; CELL MOVEMENT; ENDOTHELIAL CELLS; ESTRADIOL; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; MATRIX METALLOPROTEINASE 9; MICE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; OVARIECTOMY; STEM CELLS; TREATMENT OUTCOME;

EID: 33645734621     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.553925     Document Type: Article

References (56)

1. Morales DE, McGowan KA, Grant DS, et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation. 1995;91:755-763.
2. Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells. Circulation. 1996;94:727-733.
3. Kim-Schulze S, McGowan KA, Hubchak SC, et al. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation. 1996;94:1402-1407.
4. Johns A, Freay AD, Fraser W, et al. Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice. Endocrinology. 1996;137:4511-4513.
5. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442-447.
6. Ferrara N, Chen H, David-Smith T, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med. 1998;4:336-340.
7. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Science U S A. 1995:92:11190-11194.
8. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
9. Shi Q, Rafii S, Wu MH-D, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998;92:362-367.
10. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5:434-438.
11. Masuda H, Kalka C, Takahashi T, Iwaguro H, Hayashi S, Silver M, Chen D, Ma H, Kearney M, Losordo DW, Isner JM, Asahara T. Regulatory role of estrogen on endothelial progenitor cell kinetics for cyclic endometrial neovascularization. Circulation. 1999;100(suppl I):I-2503. Abstract.
12. Strehlow K, Wemer N, Berweiler J, et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation. 2003;107:3059-3065.
13. Iwakura A, Luedemann C, Shastry S, et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation. 2003;108:3115-3121.
14. 188. Nat Med. 1999;5:495-502.
15. Lamas GA, Pfeffer MA. Increased left ventricular volume following myocardial infarction in man. Am Heart J. 1986;111:30-35.
16. Pfeffer MA. Left ventricular remodeling after acute myocardial infarction. Annu Rev Med. 1995;46:455-466.
17. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001;103:2776-2779.
18. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007.
19. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003;9:1370-1376.
20. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625-637.
21. Heissig BWZ, Raffi S, Hattori K. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb Haemost. 2003;90:570-576.
22. Hatzopoulos AK, Folkman J, Vasile E, et al. Isolation and characterization of endothelial progenitor cells from mouse embryos. Development. 1998;125:1457-1468.
23. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood. 2000;95:952-958.
24. Unger ER, Sung JH, Manivel JC, et al. Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: a Y-chromosome specific in situ hybridization study. J Neuropathol Exp Neurol. 1993;52:460-470.
25. Quaini F, Urbanek K, Beltrami AP, et al. Chimerism of the transplanted heart. N Engl J Med. 2002;346:5-15.
26. Caplice NM, Bunch TJ, Stalboerger PG, et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A. 2003;100:4754-4759.
27. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427-435.
28. Assmus B, Schachinger V, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 2002;106:3009-3017.
29. 28a. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1-E7.
30. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593-600.
31. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194-1201.
32. Schuch G, Heymach JV, Nomi M, et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res. 2003;63:8345-8350.
33. Rafii S, Lyden D, Benezra R, et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer. 2002;2:826-835.
34. Stoll BR, Migliorini C, Kadambi A, et al. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood. 2003;102:2555-2561.
35. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-147.
36. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
37. Herrington DM, Howard TD. From presumed benefit to potential harm: hormone therapy and heart disease. N Engl J Med. 2003;349:519-521.
38. Mendelsohn ME, Karas RH. The time has come to stop letting the HERS tale wag the dogma. Circulation. 2001;104:2256-2259.
39. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994; 93:662-670.
40. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair-the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98:10344-10349.
41. Rosenfeld CR, Morriss FH Jr, Battaglia FC, et al. Effect of estradiol17beta on blood flow to reproductive and nonreproductive tissues in pregnant ewes. Am J Obstet Gynecol. 1976;124:618-629.
42. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 1990;81:1680-1687.
43. Rosano GM, Sarrel PM, Poole-Wilson PA, et al. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet. 1993;342:133-136.
44. Herrington DM, Braden GA, Williams JK, et al. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol. 1994;73:951-952.
45. Weiner CP, Lizasoain I, Baylis SA, et al. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A. 1994;91:5212-5216.
46. 2+ mobilization. Circ Res. 1997;81:885-892.
47. Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest. 1999;103:401-406.
48. Goetz RM, Thatte HS, Prabhakar P, et al. Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1999;96:2788-2793.
49. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engt J Med. 1991;324:1-8.
50. Smith PJ, Ornatsky O, Stewart DJ, et al. Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats. Circulation. 2000; 102:2983-2989.
51. Gertler MM, Driskell MM, Bland EF, et al. Clinical aspects of coronary heart disease: an analysis of 100 cases in patients 23 to 40 years of age with myocardial infarction. JAMA. 1951;146:1291-1295.
52. Maynard C, Litwin PE, Martin JS, et al. Gender differences in the treatment and outcome of acute myocardial infarction: results from the Myocardial Infarction Triage and Intervention Registry. Arch Intern Med. 1992;152:972-976.
53. Wiesneth M, Schreiner T, Friedrich W, et al. Mobilization and collection of allogeneic peripheral blood progenitor cells for transplantation. Bone Marrow Transplant. 1998;21(suppl 3):S21-S24.
54. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428-432.
55. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-805.
56. Proudler AJ, Ahmed AI, Crook D, et al. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet. 1995;346:89-90.